Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 135

1.

Diabetes and drug-associated hyperkalemia: effect of potassium monitoring.

Raebel MA, Ross C, Xu S, Roblin DW, Cheetham C, Blanchette CM, Saylor G, Smith DH.

J Gen Intern Med. 2010 Apr;25(4):326-33. doi: 10.1007/s11606-009-1228-x. Epub 2010 Jan 20.

2.

Increasingly restrictive definitions of hyperkalemia outcomes in a database study: effect on incidence estimates.

Raebel MA, Ross C, Cheetham C, Petersen H, Saylor G, Smith DH, Wright LA, Roblin DW, Xu S.

Pharmacoepidemiol Drug Saf. 2010 Jan;19(1):19-25. doi: 10.1002/pds.1882.

PMID:
19937982
3.

Patiromer in patients with kidney disease and hyperkalemia receiving RAAS inhibitors.

Weir MR, Bakris GL, Bushinsky DA, Mayo MR, Garza D, Stasiv Y, Wittes J, Christ-Schmidt H, Berman L, Pitt B; OPAL-HK Investigators.

N Engl J Med. 2015 Jan 15;372(3):211-21. doi: 10.1056/NEJMoa1410853. Epub 2014 Nov 21.

4.

The effect of ramipril and telmisartan on serum potassium and its association with cardiovascular and renal events: results from the ONTARGET trial.

Heerspink HJ, Gao P, de Zeeuw D, Clase C, Dagenais GR, Sleight P, Lonn E, Teo KT, Yusuf S, Mann JF.

Eur J Prev Cardiol. 2014 Mar;21(3):299-309. doi: 10.1177/2047487313510678. Epub 2013 Nov 4.

PMID:
24191305
5.

Potassium homeostasis and renin-angiotensin-aldosterone system inhibitors.

Weir MR, Rolfe M.

Clin J Am Soc Nephrol. 2010 Mar;5(3):531-48. doi: 10.2215/CJN.07821109. Epub 2010 Feb 11. Review.

6.

The positive predictive value of a hyperkalemia diagnosis in automated health care data.

Raebel MA, Smith ML, Saylor G, Wright LA, Cheetham C, Blanchette CM, Xu S.

Pharmacoepidemiol Drug Saf. 2010 Nov;19(11):1204-8. doi: 10.1002/pds.2030.

7.

Predictors of hyperkalemia risk after hypertension control with aldosterone blockade according to the presence or absence of chronic kidney disease.

Gwoo S, Kim YN, Shin HS, Jung YS, Rim H.

Nephron Clin Pract. 2014;128(3-4):381-6. doi: 10.1159/000369138. Epub 2015 Jan 6.

PMID:
25572273
8.

Evaluation of the treatment gap between clinical guidelines and the utilization of renin-angiotensin-aldosterone system inhibitors.

Epstein M, Reaven NL, Funk SE, McGaughey KJ, Oestreicher N, Knispel J.

Am J Manag Care. 2015 Sep;21(11 Suppl):S212-20.

9.

Predictors of hyperkalemia risk following hypertension control with aldosterone blockade.

Khosla N, Kalaitzidis R, Bakris GL.

Am J Nephrol. 2009;30(5):418-24. doi: 10.1159/000237742. Epub 2009 Sep 9.

PMID:
19738369
10.

Prevalence of hyperkalemia in adult patients taking spironolactone and angiotensin converting enzyme inhibitors or angiotensin receptor blockers.

Surabenjawong U, Thunpiphat N, Chatsiricharoenkul S, Monsomboon A.

J Med Assoc Thai. 2013 Aug;96(8):905-10.

PMID:
23991595
11.

Laboratory evaluation of potassium and creatinine among ambulatory patients prescribed spironolactone: are we monitoring for hyperkalemia?

Raebel MA, McClure DL, Chan KA, Simon SR, Feldstein AC, Lafata JE, Andrade SE, Gunter MJ, Nelson WW, Roblin D, Platt R.

Ann Pharmacother. 2007 Feb;41(2):193-200. Epub 2007 Feb 6.

PMID:
17284506
12.

Hyperkalemia: a threat to RAAS inhibition?

Schrier RW.

Nat Rev Nephrol. 2010 May;6(5):245-6. doi: 10.1038/nrneph.2010.52. No abstract available.

PMID:
20424624
13.

Effect of Patiromer on Serum Potassium Level in Patients With Hyperkalemia and Diabetic Kidney Disease: The AMETHYST-DN Randomized Clinical Trial.

Bakris GL, Pitt B, Weir MR, Freeman MW, Mayo MR, Garza D, Stasiv Y, Zawadzki R, Berman L, Bushinsky DA; AMETHYST-DN Investigators.

JAMA. 2015 Jul 14;314(2):151-61. doi: 10.1001/jama.2015.7446. Erratum in: JAMA. 2015 Aug 18;314(7):731. Dosage error in article text.

PMID:
26172895
14.

Long-term effects of aldosterone blockade in resistant hypertension associated with chronic kidney disease.

Pisoni R, Acelajado MC, Cartmill FR, Dudenbostel T, Dell'Italia LJ, Cofield SS, Oparil S, Calhoun DA.

J Hum Hypertens. 2012 Aug;26(8):502-6. doi: 10.1038/jhh.2011.60. Epub 2011 Jun 16.

PMID:
21677673
15.

Renin-angiotensin system blockade and the risk of hyperkalemia in chronic hemodialysis patients.

Knoll GA, Sahgal A, Nair RC, Graham J, van Walraven C, Burns KD.

Am J Med. 2002 Feb 1;112(2):110-4.

PMID:
11835948
16.

Mechanisms of impaired potassium handling with dual renin-angiotensin-aldosterone blockade in chronic kidney disease.

Preston RA, Afshartous D, Garg D, Medrano S, Alonso AB, Rodriguez R.

Hypertension. 2009 May;53(5):754-60. doi: 10.1161/HYPERTENSIONAHA.108.125252. Epub 2009 Mar 23.

17.

Ramipril and risk of hyperkalemia in chronic hemodialysis patients.

Krajina-Andricević M, Zibar L, Juras K, Goll-Barić S, Barbić J.

Coll Antropol. 2011 Jun;35(2):537-42.

PMID:
21755729
18.

Low Usefulness of Potassium Monitoring Among Healthy Young Women Taking Spironolactone for Acne.

Plovanich M, Weng QY, Mostaghimi A.

JAMA Dermatol. 2015 Sep;151(9):941-4. doi: 10.1001/jamadermatol.2015.34.

PMID:
25796182
19.

PEARL-HF: prevention of hyperkalemia in patients with heart failure using a novel polymeric potassium binder, RLY5016.

Buysse JM, Huang IZ, Pitt B.

Future Cardiol. 2012 Jan;8(1):17-28. doi: 10.2217/fca.11.71.

PMID:
22185443
20.

Hyperkalemia associated with use of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers.

Raebel MA.

Cardiovasc Ther. 2012 Jun;30(3):e156-66. doi: 10.1111/j.1755-5922.2010.00258.x. Epub 2011 Jan 26. Review.

PMID:
21883995

Supplemental Content

Support Center